PMID: 6538075Mar 1, 1984Paper

Optimizing metoclopramide control of cisplatin-induced emesis

Annals of Internal Medicine
B R MeyerM M Reidenberg

Abstract

Using an original high-pressure liquid chromatographic assay, we measured serum levels of metoclopramide and defined a concentration-response relationship for metoclopramide control of cisplatin-induced emesis. Using a metoclopramide regimen of 2 mg/kg body weight intravenously every 2 hours for four doses, we found that serum levels greater than 850 ng/mL immediately before the third dose were associated with complete control of emesis (less than three episodes) in 78% of patients and partial control (three to five episodes) in 18%. No patient with levels less than 850 ng/mL had complete control of emesis; only 42% had partial control (p less than 0.001). Increases in dosage for patients with low levels and poor responses improved control in four of five patients. Elderly patients had drug levels similar to those of young patients but had fewer episodes of emesis (p = 0.044), suggesting that elderly patients have increased sensitivity to this drug. The metoclopramide dose can be raised up to 2.75 mg/kg with an improvement in emetic control in patients who have an inadequate response to doses of 2 mg/kg and no toxicity.

Citations

Jan 1, 1985·European Journal of Clinical Pharmacology·R SallerH Hess
Oct 1, 1989·European Journal of Cancer & Clinical Oncology·I N OlverB L Hillcoat
Dec 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E KjellénA Olsson
Jan 1, 1984·Cancer Investigation·J J Fiore, R J Gralla
Jan 1, 1987·The American Journal of the Medical Sciences·J B Craig, B L Powell
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K MoriN Miyazawa
Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S M GrunbergP E Sanderson
Dec 1, 1990·Journal of Pain and Symptom Management·C H Wilder-SmithH J Senn
Jun 1, 1985·Journal of Clinical and Hospital Pharmacy·L J Dodds
Jan 1, 1987·Fundamental & Clinical Pharmacology·P CanalM Carton
May 1, 1987·Pharmacology & Toxicology·U AasebøJ Aarbakke
May 1, 1989·Seminars in Oncology Nursing·R A ClarkM G Kris
Feb 1, 1988·Journal of Clinical Pharmacy and Therapeutics·M E O'Brien, M H Cullen
Oct 1, 1993·Postgraduate Medicine·Syed Bilgrami, Barbara G Fallon
Mar 1, 1986·Acta Pharmacologica Et Toxicologica·L SlørdalJ Aarbakke
May 1, 1986·Pharmacotherapy·R J Cersosimo, D D Karp
Dec 1, 1988·British Journal of Clinical Pharmacology·T H MadejI Tring
Mar 31, 1986·The Medical Journal of Australia·P V Desmond, K J Watson
Oct 1, 1986·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·W J Richtsmeier, E M Mazur

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
J GaedekeH Lentzen
© 2021 Meta ULC. All rights reserved